Currently viewing the category:
"Topotarget"
Danish stocks
By Karl M. Bidstrup On 20. September 2013 · Leave a Comment · In BioPorto, Coloplast, DanDrit, Exiqon, Genmab, Topotarget, Veloxis, Zealand
Man kan så undre sig lidt over hvorfor de ikke vil give os ORR, PFS eller OS data. Men lad det nu være 🙂
—————————-
Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 01-13 / København, 24. januar 2013
Topotarget A/S (NASDAQ OMX: TOPO) meddeler, at der vil blive offentliggjort kliniske data om belinostat på det […]
Spectrum offentliggjorde igår deres 10Q filing for Q3 hvori man kunne læse nogle interssante uddybninger af deres licensaftale med det danske selskab TopoTarget vedrørende Belinostat. Nogle personer (herunder undertegnede skribent) har været bleven latterliggjort på specielt et unavngivent debatfora for at gætte på Royaly på i intervallet 10-20%. De faste Topofans på denne kanal var […]
TopoTarget A/S har idag offentliggjort at de har modtaget Orphan Drug designation i Europa, hvilket betyder hjælp til registreringsansøgningen samt markant højere priser på salget af produktet. Investorerne belønner TopoTarget aktien med at sende den 5-10% i vejret mandag. CEO Anders Vadsholt bekræfter også overfor Medwatch at dette er med til at understøtte de nuværende […]
Belinostat gets EU Orphan Drug Designation for the treatment of peripheral T-cell lymphoma
To NASDAQ OMX Copenhagen A/S Announcement no. 18-12 / Copenhagen, October 15, 2012
On October 15, 2012, the European Commission granted Topotarget A/S an Orphan Drug Designation for belinostat, its novel histone deacetylase (HDAC) inhibitor, for the treatment of peripheral T-cell lymphoma […]
Belinostat (a drug owned by Spectrum Pharmaceuticals Inc. and TopoTarget A/S).
TopoTarget posted friday that the BELIEF study have beaten the primary endpoint by the study:
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=522265&lang=en
Their Partner, Spectrum Pharmaceuticals didnt confirm those data, and there were some misunderstandings in the market. Today, spectrum announced the following comment about the BELIEF study.
http://finance.yahoo.com/news/spectrum-pharmaceuticals-provides-belinostat-registrational-112600330.html
For […]
This is a short (sort of ) article about Investment in Spectrum, and an update on TopoTarget
First and foremost, let me (investor89) say that I feel sorry for the numerous investors who have lost a lot of money on Friday’s CUP-data release. One of the wellrespected bloggers in Denmark, Renminbi, who has advocating buying shares […]
After a hectic day – its time for a little soulsearching. I have no shares in TopoTarget, but that’s just a coincidence, I might as well have had; but basically I am always a little wary with “one-trick-pony’s “- especially biotech-ponies –
Relying on just one product-line is dangerous, it’s 100% make/break … But after todays […]
Her på bagsmækken kan man gøre sig lidt tanker. Jeg har ingen aktier i TopoTarget, men det kunne såmænd godt have været tilfældet. Jeg er altid lidt bekymret ved one-trick-pony’s – især når det er biotech – det er jo 100% vind eller forsvind … Jeg tror til gengæld alle herinde på MI har godt […]
This is TopoTarget at a glance, hopefully this will provide you with an overview of one of the most exiting Biotech companies in Denmark.
Apart from telling you a bit about the investment-opportunity, I (investor89) will also make a laymans explanation of some the abbreviations you will encounter when studying TopoTarget
TopoTarget themselves describe the […]
Fredag eftermiddag kom TopoTarget rigtig i chatten – der er synes jeg god info at hente: Henning 3:56 PM Nej, jeg har kun de aktier, der kilder mest i maven, altså small cap, specielt Bioporto, Topo og Exiqon samt lidt forskellige, herunder cBrain. ndrs 3:56 PM Jeg er selv helt ude af alt bortset fra […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
